AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.
Oxidative Damage Induces Increase of Pro-Inflammatory IL-15 in Vitiligo
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Addressing Disparities in Atopic Dermatitis Education on TikTok
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media
SARS-CoV-2 Associated With Increased Incidence of Psoriasis